Biosimilars In Rheumatoid Arthritis
Biologic agents that revolutionized the treatment of patients with rheumatoid arthritis (RA) are now being reformulated as biosimilar agents. However, many questions remain regarding biosimilars: "What are they?", "Are they truly interchangeable with their reference biologics?", and "What are the clinical and financial implications of biosimilars in the treatment of patients with RA?" This archived symposium activity will provide participants with the opportunity to identify key differences between biosimilars and their reference biologics, review policy guidelines for biosimilars including naming and considerations for interchangeability, and assess data on the efficacy, safety, and clinical implications of biosimilars as part of RA patient management.
This enduring activity is intended for rheumatologists, internists, primary care providers, nurse practitioners, physician assistants, and other healthcare providers responsible for the diagnosis, treatment and/or management of patients with RA. No prerequisites required.
Upon completion of this activity, participants will be better able to do the following:
- Identify key differences between biosimilar agents and their reference biologic, including clinical data needed for approval.
- Review policy guidance on biosimilars, including naming and considerations for interchangeability.
- Assess the most up-to-date evidence on efficacy, safety and clinical implications of biosimilars as part of RA management.
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty or Presenter||Relationship Identified With|
|Roy Fleischmann, MD, MACR||Speakers' bureau, consultant/advisor, and grants/research support: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc, and Sanofi-Regeneron, UCB Pharma.|
|Professor Jürgen Braun||Has no financial relationships to disclose.|
|Stanley Cohen, MD, MACR||Has no financial relationships to disclose.|
Lou Settembrino; Christina M. Ohnsman, MD; Sandy Breslow; Leah Johnson; Alison Kemp; Bernard M. Abrams, MD; hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Amgen Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
An application has been made to the EACCME®.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|AMA PRA Category 1 Credit(s)™||1.5|
Release date: November 14, 2017
Expiration date: November 13, 2018
Estimated time to complete: 90 minutes